
The experimental CTX310 treatment lowered triglycerides and ANGPTL3 in patients with severe hypertriglyceridemia, based on data from 10 participants.
CRISPR Therapeutics reported that its experimental CTX310 treatment cut triglycerides by a mean 63% at Day 30 in 10 patients with severe hypertriglyceridemia. The Phase 1b results were presented at the American Heart Association Scientific Sessions.
The company said ANGPTL3 levels fell by a mean 65%. Participants had a median baseline triglyceride level above 1,000 mg/dL.
CRISPR Therapeutics reported no serious adverse events related to treatment and no clinically relevant elevations in liver enzymes. One participant had a Grade 2 infusion-related reaction that resolved; the infusion was completed.
As of Monday 14:35 UTC, CRISPR Therapeutics shares traded at $49.98, down 0.18% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.